460720-14-3

Basic information

• Product Name: (αS)-Cyclohexanebutanoic Acid α-[[(1S)-1-Carboxyethyl]aMino] cyclohexanebutanoic Acid α-Ethyl Ester
• Synonyms: (αS)-Cyclohexanebutanoic Acid α-[[(1S)-1-Carboxyethyl]aMino] cyclohexanebutanoic Acid α-Ethyl Ester;Enalapril Maleate IMpurity-G
• CAS NO: 460720-14-3
• Molecular Formula: C15H27NO4
• Molecular Weight: 285.37918
• Mol File: 460720-14-3.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 412.1±30.0 °C(Predicted)
• Appearance: /
• Density: 1.067±0.06 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: Ethanol (Slightly), Methanol (Slightly)
• PKA: 2.15±0.10(Predicted)
• CAS DataBase Reference: (αS)-Cyclohexanebutanoic Acid α-[[(1S)-1-Carboxyethyl]aMino] cyclohexanebutanoic Acid α-Ethyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: (αS)-Cyclohexanebutanoic Acid α-[[(1S)-1-Carboxyethyl]aMino] cyclohexanebutanoic Acid α-Ethyl Ester(460720-14-3)
• EPA Substance Registry System: (αS)-Cyclohexanebutanoic Acid α-[[(1S)-1-Carboxyethyl]aMino] cyclohexanebutanoic Acid α-Ethyl Ester(460720-14-3)

Safety Data

• Hazardous Substances Data: 460720-14-3(Hazardous Substances Data)

Usage

Description

(αS)-Cyclohexanebutanoic Acid α-[[(1S)-1-Carboxyethyl]amino]cyclohexanebutanoic Acid α-Ethyl Ester is a complex organic compound with a unique chemical structure. It is characterized by its white solid appearance and is known to be an impurity of Enalaprilat maleate.

Uses

Used in Pharmaceutical Industry:
(αS)-Cyclohexanebutanoic Acid α-[[(1S)-1-Carboxyethyl]amino]cyclohexanebutanoic Acid α-Ethyl Ester is used as an impurity in the production of Enalaprilat maleate for the pharmaceutical industry. Its presence, although as an impurity, may have implications on the efficacy and safety of the final drug product. Ensuring the quality and purity of Enalaprilat maleate is crucial for its therapeutic applications.
As an impurity in Enalaprilat maleate, (αS)-Cyclohexanebutanoic Acid α-[[(1S)-1-Carboxyethyl]amino]cyclohexanebutanoic Acid α-Ethyl Ester may also be subject to regulatory guidelines and quality control measures to minimize its potential impact on the drug's performance and patient safety.